Resource Hub

The CHOlympian Platform™ Combines Transposase-Mediated Stable Integration and Cas-CLOVER Host Modification to Deliver Highly Productive CHO Cell Lines for Biotherapeutic Manufacturing

A murine model for chronic liver-specific oligonucleotide efficacy testing

Genetically Immortalized Cells: Unlocking the Potential for Scalable Cultured Meat Production

Immortalized cells for cultured meat and seafood cell line engineering can be achieved with the piggyBac transposon technology.

How the piggyBac^® Transposon Sheds Light on Breast Cancer Drug Resistance

A new study has harnessed the power of the piggyBac transposon gene editing system to unravel key resistance mechanisms and propose a novel therapeutic strategy for breast cancer.

The MCF-7 Breast Cancer Model: A Definitive Guide

The Hera Biolabs Guide to the MCF-7 Breast Cancer Model - history, ongoing applications, and its future relevance to oncology studies.

Advantages of Utilizing the SRG rat for Investigating Tumor Metastasis

A Fred Hutch research team employed SRG rats as a model organism to improve the detection of dissemination events. Through this approach, they identified a significant increase in the abundance of circulating tumor cells (CTCs).

The SRG OncoRat for Precision Cancer Medicine

How Outsourcing to an Animal Model Provider Saves Resources for Disease Researchers

Researchers' best practices for sourcing animal models and a look at advantages of using an animal model provider like Hera BioLabs with on-site vivaria and in-house breeding programs.

Addressing the limitations of chemotherapeutic drug delivery with engineered protein polymers

The standard care of treatment for many types of cancer and infectious diseases around the world is currently chemotherapy. However, chemotherapies are widely known to be linked to severe toxicity and resistance that develop mostly due to non-specificity, leading to overall disease progression.

Cas-CLOVER achieves targeted knock-ins in induced pluripotent stem cell lines

Our better than CRISPR dimeric genome editing mechanism shines in this cell line genetic engineering use case.

Cell Line Development

OncoRat SRG – Outperforming The Mouse For Xenografts

Data indicating that the OncoRat® is more effective in xenograft studies compared to leading mouse models.

Improving Preclinical Anticancer Studies Using Rat Xenograft Model Systems

A case study showing that preclinical anticacancer studies can be vastly improved by using rats for xenografts.

SRG OncoRat , A SCID Model Ideal For Human Xenografts

A case study showing that preclinical anticacancer studies can be vastly improved by using rats for xenografts.

Frequently Asked Questions about the SRG™ Rat

SRG OncoRat , a SCID Model Ideal for Human Xenografts

Pre-clinical testing of oncology drugs can be costly and less effective. Read our datasheet and discover how oncology drug developers can benefit from our Hera SRG OncoRat.

Stable Cell Line Development with piggyBac

Achieve stable cell line development with piggyBac. Read our datasheet to learn more about this gene editing technology for therapeutics development. Reach out to us on how to start accelerate your research.

Ovarian Cancer Studies in the SRG OncoRat

Read our datasheet and learn how our Hera SRG OncoRat® is preferred for ovarian cancer PDX studies. Reach out to us on how to incorporate in your research.

Discovery To Efficacy With The Experts: Pre-clinical CRO Services At Hera BioLabs

Hera provides drug efficacy studies in a variety of in vivo models, including multiple immunodeficient mouse strains and our SRG OncoRat®. Contact us to learn more.

Prostate Cancer Studies in the SRG OncoRat

Learn about our SRG rat for oncology, how our this OncoRat aids prostate cancer studies, as well as services at Hera with PDX and standard of care options. Contact us to learn more.

piggyBac Case Study: Generating Full-length NKR-P1 Transfectants

Discover how piggyBac played a critical role in helping researchers build a comprehensive model of NKR-P1-LLT1 interactions to better understand how they function in immune-related diseases and cancer.

Orally Bioavailable Androgen Receptor Degrader, Potential Next-Generation Therapeutic for Enzalutamide-Resistant Prostate Cancer

Sprague Dawley Rag2-Null Rats Created from Engineered Spermatogonial Stem Cells Are Immunodeficient and Permissive to Human Xenografts

Local Injection of Submicron Particle Docetaxel is Associated with Tumor Eradication, Reduced Systemic Toxicity and an Immunologic Response in Uro-Oncologic Xenografts

Improving Preclinical Anticancer Studies Using Rat Xenograft Model Systems

OncoRat® SRGTM Outperforming the mouse for xenografts

View Our Webinar On The OncoRat For Xenografts And PDX

Hera’s talk at Scientist.com on using the SRG rat for the 3Rs

A Rag2/Il2rg double-knockout rat supports engraftment of human immune system for immunotherapy-based cancer efficacy studies

The SRG™ rat: A novel SCID rat for humanization studies

A Novel Immunodeficient Rat for Modeling Human Cancer

Novel immunodeficient rat models capable of supporting the growth of human tumor xenografts

Novel immunodeficient rat models offers a unique platform for drug efficacy studies in human tumor xenografts

Frequently Asked Questions about the SRG^™ Rat

Sprague Dawley Rag2 null rats created from engineered spermatogonial stem cells are immunodeficient and permissive to human xenografts

Evolution Of The Rat Model

Rat models for preclinical oncology research have evolved and their functionality for xenograft studies greatly surpasses matched mouse models.

OncoRat SRG – Outperforming The Mouse For Xenografts

Data indicating that the OncoRat® is more effective in xenograft studies compared to leading mouse models.

Improving Preclinical Anticancer Studies Using Rat Xenograft Model Systems

Hera BioLabs Offers In Vivo Bioluminescence Imaging For Pre-clinical Oncology

In vivo bioluminescent imaging in the SRGTM OncoRat® provides an ideal platform for de-risking your pipeline and developing life-saving pharmacotherapies.

SRG™ Rat (OncoRat^®) Enables Precision Medicine-Based Cancer Studies

Review of data showing high efficiency tumor take rates, growth kinetics, and successful precision medicine with difficult cell lines and PDXs

Cell Line Development

Hera Biolabs's Cas-CLOVER gene editing platform is ideal for CLD. It is easier to use than CRISPR with flexible and clear commercial terms. Send your CLD project to us to accelerate it and unburden your team.

PiggyBac Applications: Beyond Stable Cell Lines

Syngeneic Orthotopic Brain Cancer Xenografts In Rats

Learn how our highly immunocompromised rat model, the SRG Rat™ provides an advantage in orthotopic brain cancer research for better clinical interventions.

Acute Myeloid Leukemia MOLM13 And Optimus

The US FDA recently released Project Optimus, a guideline impacting clinical pipelines for acute myeloid leukemia therapy. Read our blog for more information.

Hera BioLabs Announces Exclusive Global License with Charles River

Hera BioLabs, an innovative service and technology provider with novel genetic engineering products, has announced a collaboration with Charles River Laboratories, International Inc. for a global license agreement to commercialize Hera’s SRG rat (OncoRat®). The SRG rat is the first highly immunocompromised rat model, validated for xenograft studies in oncology and infectious disease research applications. 

Rapid Creation of Bioluminescent Cell Lines for Orthotopic and Metastatic Rodent Oncology Studies

In vivo bioluminescent imaging in the SRGTM OncoRat® provides an ideal platform for de-risking your pipeline and developing life-saving pharmacotherapies.

The SRG OncoRat for Precision Cancer Medicine

In Vivo Gene Delivery Using piggyBac With Hydrodynamic Tail Vein Injection

Overview and data describing how mutant human KRAS cell lines are highly compatible with our SRG OncoRat animal research model

In Vivo Gene Delivery Using piggyBac With Hydrodynamic Tail Vein Injection

In Vivo Targeting Of Mutant KRAS Using Human Cancer Xenografts In The Immunodeficient SRG OncoRat®

Mutant human KRAS cell lines as xenografts are highly compatible with our SRG OncoRat animal research model

The Potential Of piggyBac Technology In The Rapid Determination Of Ebolavirus Infectivity In Clinical Samples

In this article, we review a recent study regarding the effective use of piggyBac in creating novel cell lines capable of efficiently detecting live ebolavirus.

New Connection Between Gut Microbes And Liver Cancer Uncovered In Mice

Researchers uncovered a unique mechanism in which gut microbes have the ability to influence the immune response against nearby liver tumors observed in mice.

Hera’s Poster For American Association for Cancer Research (AACR) Annual Meeting 2021

Emerging Trends: Utilizing Humanized Rat Models For Investigating Strategies Against HIV And Associated Pathologies

Utilize the latest advancement in humanized rat models against HIV, just like Hera BioLab's OncoRat platform. Contact us today to learn more information.

Local Injection of Submicron Particle Docetaxel is Associated with Tumor Eradication, Reduced Systemic Toxicity and an Immunologic Response in Uro-Oncologic Xenografts. Maulhardt et al

Orally -Bioavailable Androgen Receptor Degrader, Potential Next-Generation Therapeutic for Enzalutamide-Resistant Prostate Cancer. Ponnusamy and Narayana et al

HepG2-CYP™ Cell Panel

2019 AACR: OncoRat SRG: enabling xenografts and humanizing the immune system

A 2019 Clinical Cancer Research Paper Review: Improving Preclinical Anticancer Studies Using Rat Xenograft Model Systems

A case study showing that preclinical anticacancer studies can be vastly improved by using rats for xenografts.

Effect of Transfecting HepG2 with Human CYP Enzymes on Chemical Toxicity

2018 American Association for Cancer Research (AACR) Annual Meeting poster. The SRG™ rat: A novel SCID rat for humanization studies

2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. A Rag2/Il2rg double-knockout rat supports engraftment of human immune system for immunotherapy-based cancer efficacy studies

Hera’s talk at Scientist.com on using the SRG rat for the 3Rs

A Fully Immunodeficient Rat Model

HeraBioLabs | Ramesh Narayanan

HeraBioLabs | Goutham Narla

HeraBioLabs | Fallon Noto

Overcoming translational barriers by using the SRG Rat: case studies with the OncoRat®

The OncoRat – Three experts describe their experience

Hera Biolabs Receives AAALAC Accreditation For Exceptional Animal Care

One of the most important parts of the entire drug development process is the use of animals in the testing during the preclinical phase.

Fine Needle Aspirate Serial Tumor Sampling Services To Boost Your Xenograft Study Capabilities

Hera has full coverage on licensed technologies and is the first toxicology CRO focused on providing better predictability and sensitivity through genome editing technologies.

Validation Of The SRG Rat For Human Tumor Studies Published In PLOS ONE

Hera has full coverage on licensed technologies and is the first toxicology CRO focused on providing better predictability and sensitivity through genome editing technologies.

Gene Editing With piggyBac: Creating A Curative Treatment For Beta-Thalassemia

Genetic Engineering Can Soon Lead To Lifelong Cures For Diseases That Were Previously Incurable - And ß-thalassemia Is The Perfect Example.

OncoRat® Featured In Clinical Cancer Research For Prostate Cancer Studies

Hera piloted VCaP xenografts, validated/assessed engraftment efficacy, and delivered rat xenograft models for both parental VCaP and MDVR.

The OncoRat® Is The Ideal Host For Patient-Derived Xenografts Of Ovarian Cancer Cells

Advances in cytotoxic, platinum-based chemotherapeutics combined with tumor resection surgery allows approximately 80% of these patients to achieve remission.

H358 NSCLC Xenografts In Humanized Rats: The Ideal In Vivo Model For Studying KRAS Mutations

Improved in vivo xenograft models using H358 may be valuable for preclinical studies examining KRAS-targeting agents or drug combinations.

Hera Biolabs Announces Molecular Cancer Therapeutics Publication On Immunodeficient Rats For Oncology Research

Hera Biolabs, the University of Michigan, Case Western Reverse University and other collaborators are announcing a recent publication in the American Association for Cancer Research (AACR) journal, Molecular Cancer Therapeutics, entitled, "Sprague Dawley Rag2-null rats created from engineered spermatogonial stem cells are immunodeficient and permissive to human xenografts."

Breakthroughs In Gene Editing Allow For The Creation Of Superior Preclinical Oncology Models

Hera Biolabs has used its proprietary gene editing technologies to develop ideal rat models for use in pre-clinical oncology research by oncology CROs.

The OncoRat®: Hosting Valuable Tumor Xenograft Models That Are Difficult Or Impossible To Study Using In Vitro Or Mouse Models

Xenograft models are an imperative preclinical model for understanding the role of specific oncogenic drivers, tumor suppressor losses, and homogenous cancer cells.

Patient Derived Xenograft Studies From Wider Varieties Of Patient Sub-Populations Promise Improved Clinical Trial Selection And Design

Around 85% of preclinical drugs entering clinical trials in oncology never make it past Phase 1 because they fail to demonstrate sufficient efficacy due to testing in unselected patient populations. Many of these failed agents are targeted therapies, meaning that they target specific oncogenic driver mutations.

OncoRat® PDX Models Highlighted In Drug Discovery News (DDN) Special Report On Cancer: Aiming For Avatars

While advances in in-vitro platforms have allowed researchers to better visually monitor a variety of aspects of tumor biology, a significant limitation of 3D cultured models for patient therapeutic monitoring or “patient avatars” is the lack of important components, such as the influence of surrounding tissues and potential cell-to-cell interactions, when studying cancer progression, treatment responses and outcomes.

Understanding Transporter-Mediated Drug-Drug Interactions Using Humanized Liver Mice

Humanized liver mice such as PXB and TK-NOG mice could play an important role in drug discovery and the evaluation of DDIs in a preclinical setting.

Using Patient Derived Xenografts To Improve Therapeutic Cancer Treatments

An understanding of human tumors has created a solid foundation for the creation of new anti-cancer treatments (many of which involve antineoplastic compounds).

Humanized Mouse Models Advance Immunotherapeutic Strategies In Treatment Of Type 1 Diabetes

The future holds with regards to the treatment of T1D and this could be a major breakthrough in the understanding of the disease.

Humanized Mice Allow For Better Understanding Of Interactions Between VACV & Immune System

“Creating a favorable microenvironment for induction of optimal anti-tumor immune responses” are urgently needed to move the needle forward on VACV-based treatments in a clinical environment.

Humanized Mouse Model Allows For Study Of Immune Response To Decellularized ECM Biomaterials

Humanized mouse models will allow for further study of human immune cell responses to biomaterials in an in vivo environment.

Early Discovery In Rats And Humanized Rodents

We offer a range of preliminary in vivo capabilities as well as the ability to screen compounds in both traditional animal rodent models.

HIS Mice Provide New Preclinical Model For Human Skin Immunity

By injecting this model with human antigen-presenting cells (APC) at the treatment site, Centlivre et al were able to invoke an immune response in the HIS mouse.

What’s Old Is New Again: Chemical Carcinogenesis Models Of Cancer

In vivo chemical carcinogenesis models may just have what it takes for researchers to better understand the necessary pathways to prevent, treat and ultimately cure human cancer.

New Mouse Model Enables In Vivo Assessment Of Immunotherapies For Treating CGD

New humanized NSG mouse xenograft prove research surrounding other human phagocyte deficiencies and in the study of infections frequently associated with human cell transplant procedures.

Patient Derived Xenografts Possess Significant Advantages In The Study Of Urological Tumors

For researchers to model this complexity ongoing studies involving PDX murine models continuously show advantages when compared to the conventional CDX mice.

Bacterial Carriers Offer New Hope In The Treatment Of Glioblastoma

The bacterial carrier most definitely opens the door for the creation of some highly targeted therapies that could effectively suppress GBM tumor growth.

Chimeric Humanized Mouse Models: Understanding Human And Mouse Cell Interactions

A result of the species mismatch between human and mouse cells certain deficiencies are increasingly common.

Transposon Mutagenesis Helps Identify Genes Mediating Drug Resistance In The Treatment Of CLL

PiggyBac transposon mutagenesis screens have the ability to help lead the way when it comes to identifying genes that mediate patient sensitivity to specific drug therapies.

PDX Models of Lung Cancer Closely Mimic Characteristics Of Patient Primary Tumors

High throughput screening strategy, using larger PDX models, may be helpful in identifying broader responses to novel therapeutics in a pre-clinical setting.

Orthotopic vs. Subcutaneous Xenograft Models of Human Cancer

Orthotopic xenograft models seem to more closely mimic the tumor micro-environment and metastases as observed in human prostate cancer patients according to Journal of Cellular Biochemistry.

HIV-1 Gene Therapies Considered: RNAi Versus CRISPR-Cas

As additional in vivo testing in humanized rodent models continues, researchers will develop efficient and safer therapeutic strategies designed to suppress the replication of HIV-1.

Humanized Mouse Xenograft Models: The Best Of Both Worlds

Immunized mice allowed for researchers to examine cancer xenograft growth in the context of a human-like immune system and resulting tumor microenvironment.

Xenograft Rat Models Give Hope To New Therapeutic Treatments For Leukemia

There is significant preclinical rational for clinical investigation of pharmacologic DOT1L inhibitors for DNMT3A-mutant leukemia (AML).

Humanized MDCK Cells – Case Study

Faster & cleaner transporter assays with cPgp/cBcrp double knockout MDCKII cell line, MDCKII-BP-null™ cells, and “humanized” cell lines stably expressing ABCB1 (MDR1) gene encoding hPGP and ABCG2 gene encoding hBCRP

piggyBac Creates Human SIRPA BAC Transgenic Rat Models

Overview of obtaining human SIRPA BAC transgenic rat models for preclinical research using piggyBac transposase/transposon gene editing.

Humanized Mouse Models Give Hope To Allergy Research

The newly created BLT humanized mouse model offers tremendous implications for the future of allergy research and gives hope that a rat model with a humanized immune system.

Hera BioLabs In Genetic Engineering News

Hera BioLabs and our VP of Research and Development Tseten Yeshi was featured this week in the Genetic Engineering News (GEN) article titled Humanizing Animal Models for Immuno-oncology.

Advancements In Stem Cell-Based Therapies For Malignant Brain Tumors

MSCs, particularly human adipose-derived mesenchymal stem cells (hAMSCs), have great potential as brain tumor-targeting carriers of drug therapies.

Hera BioLabs Receives PHS Approved Animal Welfare Assurance

Hera announced today that it has received PHS Assurance on humane care and use of laboratory animals from NIH Office of Laboratory Animal Welfare (OLAW).

New Transgenic Rat Models Offer Superior Representation Of Human Cancers

Utilizing embryonic injection of CRISPR, rodent models with spontaneous gene mutations can be created on most strains, leading to faster transgenic model creation timelines.

Could Xenograft Rats Be The Future of Leukemia Research?

In-vivo imaging techniques will be able to monitor and evaluate the efficacy of preclinical therapies with hopes of a cure for leukemia and other cancers.